Home › Funds › Live Oak Health Sciences Fund
Fund family: OAK ASSOCIATES FUNDS · Filed by OAK ASSOCIATES FUNDS (CIK 1050918) · SEC series S000006542
Ticker: LOGSX (C000017877)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 302 with, 14 against, 0 abstentions (not counted as with management). Shareholder proposals: 4 FOR, 10 AGAINST, 0 abstained, by the filing’s own vote-source field.
No item-level comparison with other OAK ASSOCIATES FUNDS funds is possible: no ballot item of this fund was voted by at least three other funds of the family with a clear majority.
The same votes as “with management” above, by the sector of the company voted on. 91.1% of this fund’s 316 such votes could be given a sector; the other 28 (8.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 288 | 14 | 4.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 226 | 0 |
| Say-on-Pay | 26 | 0 |
| Audit-related | 24 | 0 |
| Corporate Governance | 15 | 7 |
| Compensation | 9 | 0 |
| Capital Structure | 7 | 0 |
| Other Social Issues | 4 | 4 |
| Environment or Climate | 3 | 3 |
| Shareholder Rights and Defenses | 3 | 0 |
| Other | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| McKesson Corporation | July 30, 2025 | $5M | 14 | 0 |
| Cardinal Health, Inc. | November 5, 2025 | $5M | 14 | 0 |
| Exelixis, Inc. | May 26, 2026 | $4M | 14 | 0 |
| Amgen Inc. | May 19, 2026 | $3M | 15 | 1 |
| United Therapeutics Corporation | June 26, 2026 | $3M | 15 | 0 |
| Regeneron Pharmaceuticals, Inc. | June 12, 2026 | $3M | 7 | 0 |
| Cencora, Inc. | March 5, 2026 | $3M | 13 | 0 |
| Johnson & Johnson | April 23, 2026 | $2M | 15 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 15, 2026 | Medpace Holdings, Inc. | Stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting, if properly presented at the meeting. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| April 22, 2026 | The Cigna Group | Shareholder Proposal - Shareholder Right to Act by Written Consent Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| May 13, 2026 | Elevance Health, Inc. | Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
318 ballot items at 25 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Live Oak Health Sciences Fund (LOGSX) voted at 25 shareholder meetings of 25 companies, on 318 ballot items in all. Where management made a recommendation, the fund followed it on 95.6% of the items and voted against it 14 times. Its most frequent area of disagreement was corporate governance (7 of its votes against management). It voted on 14 shareholder proposals.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.